Logo for Alzinova

Alzinova Investor Relations Material

Latest events

Logo for Alzinova

Q4 2023

28 Feb, 2024
Logo for Alzinova

Q3 2023

2 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Alzinova

Access all reports
Alzinova AB, a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease. The lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers